One CSPC Pharmaceutical Group Insider Raised Their Stake In The Previous Year
One CSPC Pharmaceutical Group Insider Raised Their Stake In The Previous Year
Looking at CSPC Pharmaceutical Group Limited's (HKG:1093 ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.
纵观去年石药集团有限公司(HKG: 1093)的内幕交易,我们可以看到内部人士是净买家。也就是说,内部人士购买的股票数量多于出售的股票数量。
While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.
尽管在长期投资中,内幕交易并不是最重要的事情,但我们认为完全忽视内幕交易是愚蠢的。
View our latest analysis for CSPC Pharmaceutical Group
查看我们对石药集团的最新分析
CSPC Pharmaceutical Group Insider Transactions Over The Last Year
CSPC制药集团去年的内幕交易
Over the last year, we can see that the biggest insider purchase was by Executive Chairman Dongchen Cai for HK$13m worth of shares, at about HK$7.69 per share. That means that an insider was happy to buy shares at above the current price of HK$5.99. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Dongchen Cai was the only individual insider to buy during the last year.
在过去的一年中,我们可以看到,最大的内幕收购是执行主席蔡东晨以每股约7.69港元的价格购买了价值1300万港元的股票。这意味着内部人士乐于以高于当前5.99港元的价格购买股票。从那以后,他们的观点可能发生了变化,但至少这表明他们当时感到乐观。对我们来说,考虑内部人士为股票支付的价格非常重要。令人鼓舞的是,一位内部人士的股价高于当前的股价,这表明即使在更高的水平上,他们也看到了价值。蔡东晨是去年唯一买入的内部人士。
Dongchen Cai bought 4.25m shares over the last 12 months at an average price of HK$7.59. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
蔡东晨在过去的12个月中以7.59港元的平均价格购买了425万股股票。您可以看到下图所示的去年的内幕交易(公司和个人)。如果你想确切地知道谁卖了、卖了多少以及何时出售,只需点击下图!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240128/0-db4b08d0a42b1b06ad6d5727090a67d5-0-d0fd83635242461eb3c4e0d5da0a1a4a.png/big)
CSPC Pharmaceutical Group is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
CSPC制药集团并不是内部人士唯一买入的股票。对于那些喜欢寻找中奖投资的人来说,这份最近有内幕收购的成长型公司的免费名单可能只是门票。
Insider Ownership
内部所有权
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. CSPC Pharmaceutical Group insiders own about HK$17b worth of shares (which is 24% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
查看公司的内部持股总量可以帮助你了解他们是否与普通股股东保持一致。我认为,如果内部人士拥有该公司的大量股份,这是一个好兆头。石药集团内部人士拥有价值约170亿港元的股份(占该公司24%的股份)。大多数股东会很高兴看到这种内部所有权,因为这表明管理层的激励措施与其他股东非常一致。
So What Do The CSPC Pharmaceutical Group Insider Transactions Indicate?
那么,CSPC制药集团的内幕交易表明了什么?
It doesn't really mean much that no insider has traded CSPC Pharmaceutical Group shares in the last quarter. However, our analysis of transactions over the last year is heartening. It would be great to see more insider buying, but overall it seems like CSPC Pharmaceutical Group insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. While conducting our analysis, we found that CSPC Pharmaceutical Group has 1 warning sign and it would be unwise to ignore it.
上个季度没有内部人士交易过CSPC制药集团的股票,这并不意味着什么。但是,我们对去年交易的分析令人鼓舞。很高兴看到更多的内幕收购,但总体而言,CSPC Pharmaceutical Group的内部人士似乎相当一致(拥有该公司的很大一部分股份),对未来持乐观态度。因此,这些内幕交易可以帮助我们建立有关股票的论点,但也值得了解该公司面临的风险。在进行分析时,我们发现CSPC制药集团有1个警告信号,忽视它是不明智的。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果你想看看另一家公司——一家财务状况可能优越的公司——那么千万不要错过这份免费的股本回报率高、债务低的有趣公司的名单。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。